Overview of lymphoma.- Pathogenesis of lymphomas.- Classification of Hodgkin and non-Hodgkin lymphoma.- Case Study Section One: Indolent B-Cell Lymphomas.- Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia.- Follicular lymphoma.- Lymphoplasmacytic lymphoma in the era of next generation sequencing.- Case Study Section Two: Aggressive B-Cell Lymphomas.- Mantle cell lymphoma.- Burkitt lymphoma.- Diffuse large B-cell lymphoma.- Case Study Section Three: T-Cell Lymphomas.- Cutaneous T-cell lymphoma.- Systemic T-cell lymphoma.- Case Study Section Four: Hodgkin Lymphoma.- Hodgkin lymphoma.- Case Study Section Five: Lymphomas in Special Clinical Situations.- Acquired immunodeficiency syndrome-related lymphoma.- Central nervous system lymphoma.- Conclusion.
Jasmine Zain MD, is an associate clinical professor in the
Department of Hematology & Hematopoietic Cell Transplantation.
Additionally, she is the Tim Nesvig Lymphoma Research Fellow, as
well as Director of the T cell Lymphoma Program at the Toni
Stephenson Lymphoma Center at City of Hope. Dr Zain obtained her
medical degree from Fatima Jinnah Medical College for Women in
Lahore, Pakistan. She went on to complete an internship and
residency at North Shore Hospital of Forest Hills in Forest Hills,
NY, followed by a hematology/oncology fellowship at New York
University Medical Center. She then took a position at The Brooklyn
Hospital as an attending physician, followed by an appointment as
assistant professor in the Department of Medicine at the University
of Connecticut. Dr Zain first joined City of Hope where she
specialized in the treatment of patients with cutaneous T-cell
lymphoma, allogeneic stem cell transplantation, and early phase
clinical trials in hematologic malignancies. She left City of Hope
to assume a leadership position as Director of the bone marrow
transplant program at New York University Langone Medical Center,
before joining the faculty at Columbia University in 2012.
Triple-board certified in hematology, oncology and internal
medicine, Dr Zain is an active member of several professional
associations, and has published more than 78 peer-reviewed
publications, abstracts, and book chapters. She served as an
Associate Editor for two journals in her field – Clinical Lymphoma
and Myeloma, and Clinical Cancer Research – and has been invited to
speak both nationally and internationally. Dr Zain is a superb
clinician, a productive and creative clinical researcher, and an
outstanding and experienced teacher.
Larry W Kwak MD, PhD, joined City of Hope as inaugural Cancer Center Associate Director, Translational Research & Developmental Therapeutics in April 2015. Dr Kwak graduated from the 6-year combined BS-MD Honors Program in Medical Education from Northwestern University Medical School in 1982 and earned his PhD in tumor cell biology there in 1984. He then completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California. Thereafter, he served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute (NCI) for 12 years. His NCI laboratory is credited with the pioneering bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies, which was recently reported as positive in a landmark national Phase III clinical trial. This was one of three recently positive Phase III clinical trials of cancer vaccine immunotherapy. From 2004–14 Dr Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, MD Anderson Cancer Center in Houston, Texas, where he also held the Justin Distinguished Chair in Leukemia Research. As Chair, his department successfully captured extensive research support, including large team science grants, such as two SPORE grants in Lymphoma and Multiple Myeloma, respectively, from the NCI and a SCOR program project grant awarded by the Leukemia and Lymphoma Society. He also led the expansion of the department’s laboratory research space and launched biospecimens banks to support translational research. A committed physician, scientist, and mentor, his vision is to assemble and lead research teams to integrate basic discoveries from academic laboratories with translational clinical development to first-in-human clinical trials of novel ‘homegrown’ therapeutics, such as next generation cancer immunotherapies. He plays a key role in the future direction of City of Hope’s translational and precision medicine and ‘teamwork science’ initiatives. He is an expert in the clinical management of patients with low grade lymphomas. In 2010 Dr Kwak was named to the TIME 100, one of the world’s 100 most influential people by TIME magazine, for his 20 year commitment to the science of cancer immunotherapy. In 2016, he was awarded the Ho-Am Prize in Medicine for his pioneering research in cancer immunotherapy.